Globus Medical (NYSE: GMED) insider transactions
In the twelve months to 10 November 2026, executives and directors of Globus Medical reported 13 open-market sales of 200,636 shares ($17.1m) and 0 open-market purchases, by 7 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 4 November 2026 | Rhoads Ann D | Director | Open-market sale, 10b5-1 plan | −5,000 | $85.00 | 35,384 | Form 4 |
| 15 September 2026 | Tobin James R | Director | Option exercise | +15,000 | $53.75 | 15,000 | Form 4 |
| 15 September 2026 | Tobin James R | Director | Option exercise | +15,000 | $63.68 | 30,000 | Form 4 |
| 15 September 2026 | Tobin James R | Director | Open-market sale | −30,000 | $74.58 | 0 | Form 4 |
| 18 August 2026 | Zarrilli Stephen T | Director | Option exercise | +25,000 | $53.27 | 25,000 | Form 4 |
| 18 August 2026 | Zarrilli Stephen T | Director | Open-market sale | −25,000 | $87.04 | 0 | Form 4 |
| 27 July 2026 | Davidar David D | Director | Gift | −2,500 | — | 507,675 | Form 4 |
| 5 June 2026 | Davidar David D | Director | Option exercise | +25,000 | $26.27 | 535,175 | Form 4 |
| 5 June 2026 | Davidar David D | Director | Open-market sale | −25,000 | $80.76 | 510,175 | Form 4 |
| 4 June 2026 | Rhoads Ann D | Director | Option exercise | +25,000 | $26.27 | 40,384 | Form 4 |
| 25 February 2026 | Huller Kelly | EVP, GC, Corporate Secretary | Option exercise | +20,000 | $43.58 | 20,000 | Form 4 |
| 25 February 2026 | Huller Kelly | EVP, GC, Corporate Secretary | Open-market sale | −20,000 | $94.50 | 0 | Form 4 |
| 12 February 2026 | Huller Kelly | EVP, GC, Corporate Secretary | Option exercise | +10,000 | $45.64 | 10,000 | Form 4 |
| 12 February 2026 | Huller Kelly | EVP, GC, Corporate Secretary | Open-market sale | −10,000 | $87.67 | 0 | Form 4 |
| 8 January 2026 | Norwalk Leslie V | Director | Open-market sale | −2,000 | $101.10 | 10,419 | Form 4 |
| 8 January 2026 | Kline Kyle | Senior Vice President, CFO | Option exercise | +3,594 | $51.87 | 3,594 | Form 4 |
| 8 January 2026 | Kline Kyle | Senior Vice President, CFO | Open-market sale | −3,594 | $101.10 | 0 | Form 4 |
| 12 December 2025 | Norwalk Leslie V | Director | Open-market sale | −4,000 | $88.85 | 12,419 | Form 4 |
| 8 December 2025 | Paul David C | Executive Chairman | Option exercise | +34,375 | $25.52 | 60,417 | Form 4 |
| 1 December 2025 | Kline Kyle | Senior Vice President, CFO | Option exercise | +3,646 | $53.14 | 3,646 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Globus Medical page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.